Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gaedigk

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|November 1, 2007
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotypeA Gaedigk, S D Simon, R E Pearce, et al.
Pharmacogenetics|September 10, 1998
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populationsA Gaedigk, R F Tyndale, M Jurima-Romet, et al.
Pharmacogenetics|March 25, 1998
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationE U Griese, U M Zanger, U Brudermanns, et al.
Clinical Pharmacology and Therapeutics|December 15, 2015
Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHDJ T Brown, S M Abdel-Rahman, L van Haandel, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2007
Effect of arylamine acetyltransferase Nat3 gene knockout on N-acetylation in the mouseK S Sugamori, D Brenneman, S Wong, et al.
Clinical Pharmacology and Therapeutics|August 23, 2008
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control studyP Madadi, C J D Ross, M R Hayden, et al.
Clinical Toxicology (Philadelphia, Pa.)|July 17, 2013
Polymorphisms in CYP2D6 may predict methamphetamine related heart failureM E Sutter, A Gaedigk, T E Albertson, et al.
Nature|October 25, 1990
Identification of the primary gene defect at the cytochrome P450 CYP2D locusA C Gough, J S Miles, N K Spurr, et al.
Pharmacogenetics|April 26, 2000
Limitations of dextromethorphan N-demethylation as a measure of CYP3A activityA D Kashuba, A N Nafziger, G L Kearns, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphanK Abduljalil, D Frank, A Gaedigk, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|November 1, 2007
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotypeA Gaedigk, S D Simon, R E Pearce, et al.
Pharmacogenetics|September 10, 1998
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populationsA Gaedigk, R F Tyndale, M Jurima-Romet, et al.
Pharmacogenetics|March 25, 1998
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationE U Griese, U M Zanger, U Brudermanns, et al.
Clinical Pharmacology and Therapeutics|December 15, 2015
Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHDJ T Brown, S M Abdel-Rahman, L van Haandel, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2007
Effect of arylamine acetyltransferase Nat3 gene knockout on N-acetylation in the mouseK S Sugamori, D Brenneman, S Wong, et al.
Clinical Pharmacology and Therapeutics|August 23, 2008
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control studyP Madadi, C J D Ross, M R Hayden, et al.
Clinical Toxicology (Philadelphia, Pa.)|July 17, 2013
Polymorphisms in CYP2D6 may predict methamphetamine related heart failureM E Sutter, A Gaedigk, T E Albertson, et al.
Nature|October 25, 1990
Identification of the primary gene defect at the cytochrome P450 CYP2D locusA C Gough, J S Miles, N K Spurr, et al.
Pharmacogenetics|April 26, 2000
Limitations of dextromethorphan N-demethylation as a measure of CYP3A activityA D Kashuba, A N Nafziger, G L Kearns, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphanK Abduljalil, D Frank, A Gaedigk, et al.
Pageof 5